Trials / Completed
CompletedNCT05637255
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Sylentis, S.A. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYL1801 | 1 drop in the eligible eye |
Timeline
- Start date
- 2022-11-22
- Primary completion
- 2024-12-19
- Completion
- 2024-12-19
- First posted
- 2022-12-05
- Last updated
- 2026-04-13
Locations
16 sites across 3 countries: Czechia, Poland, Slovakia
Source: ClinicalTrials.gov record NCT05637255. Inclusion in this directory is not an endorsement.